Noxopharm’s SOF-SKN shows prolonged skin retention in preclinical study

Noxopharm Ltd. ( (AU:NOX) ) just unveiled an announcement.

Noxopharm Limited has reported new preclinical pharmacokinetic data for its cutaneous lupus candidate SOF-SKN, showing that the active ingredient SOF-16 has a skin half-life of about 3.5 days in both normal and disease-like tissue. The long residence time, combined with its established safety profile, suggests the drug could enable sustained therapeutic activity with less frequent dosing, potentially improving convenience and adherence for patients with chronic inflammatory skin conditions.

The study also demonstrated that SOF-16 remains largely confined to the epidermis and dermis, with negligible systemic absorption, supporting the drug’s design to suppress local immune activation while avoiding broader immunosuppression. On the back of these results, Noxopharm is engaging a contract research organisation to prepare for a human trial, a step that could strengthen its position in the growing autoimmune dermatology market and pave the way for broader applications of its Sofra technology platform.

More about Noxopharm Ltd.

Noxopharm Limited is a clinical-stage biotechnology company focused on developing immunology-based treatments, with a key emphasis on chronic inflammatory and autoimmune diseases. Its lead dermatology candidate, SOF-SKN, targets cutaneous lupus erythematosus and may be extended to other autoimmune-related skin conditions, addressing a global market for CLE valued at more than US$3.3 billion.

Average Trading Volume: 182,309

Technical Sentiment Signal: Sell

Current Market Cap: A$19.05M

For an in-depth examination of NOX stock, go to TipRanks’ Overview page.